Neuroendocrine tumours: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

24 of 1,062 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €268,569· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €4,574,378· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norway· EU contribution €4,773,849· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxembourg· EU contribution €14,837,694· until Dec 2029· 13 countries

5 of 7 running projects, newest first. Listed amounts together: €37.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Updated 13 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  NCT07061080· Grupo Espanol de Tumores Neuroendocrinos· Updated 18 Sept 2026

  “AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.”Registry text, quoted unchanged. Source

• Terminated

  SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

  NCT01039922· Insel Gruppe AG, University Hospital Bern· Updated 11 Sept 2026

  “The register will no longer be maintained on a prospective basis”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

  NCT03145857· AHS Cancer Control Alberta· Updated 3 Sept 2026

  “The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is considered standard of care. Furthermore, the manufacturer of the study Investigational Product (IP) is no longer supplying the IP.”Registry text, quoted unchanged. Source

• Suspended

  A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

  NCT01876771· AHS Cancer Control Alberta· Updated 27 Jul 2026

  “Study closed to accrual given widespread availability of the similar marketed product, Lutathera(R), and the corresponding lack of accrual to the study.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

  NCT06158516· Changhai Hospital· Updated 11 Jun 2026

  “This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.”Registry text, quoted unchanged. Source

• Withdrawn

  Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  NCT07328490· National Cancer Institute (NCI)· Updated 28 Apr 2026

  “Study drug supplier withdrew support; no participants were enrolled.”Registry text, quoted unchanged. Source

• Terminated

  Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

  NCT04754425· M.D. Anderson Cancer Center· Updated 6 Feb 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

  NCT05987176· Imperial College London· Updated 14 Jan 2026

  “The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  NCT04665739· National Cancer Institute (NCI)· Source

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Boehringer Ingelheim· Source

• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

  NCT00923026· National Cancer Institute (NCI)· Source

• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

  NCT04750954· National Cancer Institute (NCI)· Source

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

  NCT06406465· National Cancer Institute (NCI)· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  NCT05058651· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 201
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

See which targets of this disease your abstract mentions, and go to the people working on them.